Page 121 - Read Online

Oo et al. Mini-invasive Surg 2019;3:13 I http://dx.doi.org/10.20517/2574-1225.2019.02 Page 9 of 9

46. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, et al. Minimally invasive versus open oesophagectomy for
patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012;379:1887-92.
47. Biere SSAY, Cuesta MA, van der Peet DL. Minimally invasive versus open esophagectomy for cancer: a systematic review and meta-
analysis. Minerva Chir 2009;121-33.
48. Verhage RJJ, Hazebroek EJ, Boone J, Van Hillegersberg R. Minimally invasive surgery compared to open procedures in esophagectomy
for cancer: a systematic review of the literature. Minerva Chir 2009;64:135-46.
49. Santillan AA, Farma JM, Meredith KL, Shah NR, Kelley ST. Minimally invasive surgery for esophageal cancer. J Natl Compr Canc
Netw 2008:879-84.
50. Cunningham D, Allum WH, Stenning SP, Thompson GN, Van de Velde CJ, et al. Perioperative chemotherapy versus surgery alone for
resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
51. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in
oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33.
52. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy for
esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
53. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al. Chemoradiotherapy after surgery compared with surgery alone
for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
54. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy
(CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
55. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med 2007;357:1810-20.
56. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy plus
surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet
Oncol 2015;16:1090-8.
57. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, et al. Phase III comparison of preoperative chemotherapy compared with
chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6.
58. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, et al. Survival after neoadjuvant chemotherapy or
chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681-92.